Agenda

Date and TimeTitle
Oct 29, 2021
12:45pm - 1:45pm (Eastern)
Resolving Therapeutic Inertia Using Actionable CGM Guidance

The progressive nature of type 2 diabetes changes diabetes management over time in a variety of ways and is different for each person living with diabetes. Continuous glucose monitoring (CGM) provides a visual context to an individual’s current time-in-range and helps both the person and the healthcare professional identify areas to improve. This presentation will review the limitations of both A1C and blood glucose monitoring while highlighting the benefits of the Dexcom G6 real-time CGM system and Dexcom G6 Professional system in type 2 diabetes management. You will also learn to interpret Dexcom CLARITY reports through patient case studies, and how CLARITY data can be used for clinical guidance and therapeutic intervention. Learn to use CGM data and reports to inform treatment decisions via case studies

Sponsored by Dexcom

This is a Non CME/CE Presentation.

Oct 26, 2022
7:00am - 10:30am (Central)
Session I: Breast Cancer Risk Assessment and Screening

x:xx pm CT | Session

69 days to start
Oct 26, 2022
11:35am - 2:25pm (Central)
Session II: PET Imaging and Beyond

x:xx am | Session

69 days to start
Oct 26, 2022
4:00pm - 5:30pm (Central)
Session III: The Reading Room

x:xx pm | Session

69 days to start
Oct 27, 2022
8:10am - 10:15am (Central)
Session IV: Early Disease Considerations in HR-Positive Breast Cancer

x:xx pm | Session

70 days to start
Oct 27, 2022
12:55pm - 3:00pm (Central)
Session V: Metastatic Disease Considerations in HR-Positive Breast Cancer

x:xx pm | Session

70 days to start
Oct 27, 2022
3:10pm - 5:15pm (Central)
Session VI: Special Topics in HR-Positive Breast Cancer

x:xx pm | Session

70 days to start
Oct 28, 2022
8:10am - 10:15am (Central)
Session VII: Early Disease Considerations in HER2-Positive Breast Cancer

x:xx pm | Session

71 days to start
Oct 28, 2022
12:55pm - 3:00pm (Central)
Session VIII: Metastatic Disease Consderations in HER2-Positive Breast Cancer

x:xx pm | Session

71 days to start
Oct 28, 2022
3:10pm - 5:15pm (Central)
Session IX: Special Topics in HER2-Positive Breast Cancer

x:xx pm | Session

71 days to start
Oct 29, 2022
7:00am - 9:05am (Central)
Session X: Early Disease Considerations in Triple Negative Breast Cancer

x:xx pm | Session

72 days to start
Oct 29, 2022
10:30am - 1:00pm (Central)
Session XI: Metastatic Disease Considerations in Triple Negative Breast Cancer

x:xx pm | Session

72 days to start
Apr 7, 2023
11:00am - 12:00pm (Eastern)
Sample Live Non-CME/CE Bonus Presentation

Join us to learn more about smart insulin therapy featuring InPen™ Smart Insulin Pen. Topics of discussion will include:Building a data driven care approach with smart insulin pens to address the challenges of insulin therapy; How to have productive conversations with your insulin therapy patients using the InPen™ Insights Report; Putting it all together: Case study

Sponsored by Medtronic

This is a Non CME/CE Presentation.

232 days to start
Aug 4, 2023
4:30pm - 5:00pm (Eastern)
Visit Exhibit and Poster Halls

Click HERE to visit the exhibit hall.

Click HERE to visit the poster hall.

351 days to start
Aug 4, 2023
6:30pm - 7:45pm (Eastern)
Sample CME/CE Independent Symposium: Title Goes Here

Moderator: Seth J. Baum, MD
Panelists: Pamela B. Morris, MD, Pam R. Taub MD, and James A. Underberg, MD, MS

Program Description: Put this here if applicable. If there is not one, then just remove this.

1 Additional hour of CME credit

Click here to claim credit

Supported by an independent educational grant from Esperion Therapeutics

ACCREDITATION STATEMENT 
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

For Physicians
Medscape, LLC designates this live event for a maximum of 4.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Physician Assistants
Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 4.0 AAPA Category 1 CME credits. Approval is valid until 09/30/21. PAs should only claim credit commensurate with the extent of their participation.

For Nurses
Awarded 4.0 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.0 nursing pharmacology content hours.

351 days to start